— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children
Most Popular
Domino’s Pizza (DPZ) Q1 2025 Earnings: Key financials and quarterly highlights
Domino’s Pizza, Inc. (NASDAQ: DPZ) reported its first quarter 2025 earnings results today. Revenues increased 2.5% year-over-year to $1.11 billion, primarily due to higher US franchise advertising revenues, higher supply
Earnings Preview: Microsoft expected to report higher Q3 revenue, profit
Tech behemoth Microsoft Corp. (NASDAQ: MSFT) is preparing to report its third-quarter 2025 results, amid expectations for a year-over-year increase in revenue and earnings. The company has performed well recently,
What to expect when eBay (EBAY) reports its Q1 2025 earnings results
Shares of eBay Inc. (NASDAQ: EBAY) were down slightly in midday trade on Friday. The stock has gained 8% year-to-date. The ecommerce giant is slated to report its earnings results
Comments
Comments are closed.